Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
Primary Aldosteronism, Endocrine Hypertension
About this trial
This is an interventional treatment trial for Primary Aldosteronism focused on measuring Primary aldosteronism, Calcium channel blocker, Aldosterone
Eligibility Criteria
Inclusion Criteria: Confirmed PA, as demonstrated by a positive screening test and internationally endorsed confirmatory test (saline suppression test, captopril challenge test) Adults > 18 years of age Able and willing to give informed consent Exclusion Criteria: Uncontrolled hypertension requiring use of MRA Unwilling or unable to give consent Below age 18 or above age 90 years Allergy to cinnarizine or nifedipine or their excipients Existing use of cinnarizine or nifedipine for an alternative indication Breastfeeding or pregnant women Diagnosis of Parkinson's disease Severe hepatic or renal insufficiency Concurrent use of sedating central nervous system (CNS) depressants or rifampicin Porphyria Cardiogenic shock, clinically significant aortic stenosis, unstable angina, within one month of a myocardial infarction Previous gastro-intestinal or oesophageal obstruction or ileostomy
Sites / Locations
- St Bartholomew's HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Cinnarizine and nifedipine
Drug 1 for 2 weeks, 2 weeks of washout, then Drug 2 for 2 weeks Drug 1 and 2, in no specified order, Cinnarizine 30 mg oral TDS and Nifedipine 60 mg oral daily